drugset / Trial / NCT05773092
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
Phase 2
Active not recruiting
30 enrolled
National Cancer Centre, Singapore
Taiho Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to determine best overall response rate (BOR) based on radiological assessment per RECIST v1.1 to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2025-10-24
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 40 mg | Oral |